IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc. filed a Current Report on Form 8-K dated May 12, 2023, under Item 2.02 to announce financial results for the quarter ended March 31, 2023. The filing furnishes a related press release as Exhibit 99.1. IN8bio is an emerging growth company, and its common stock trades on Nasdaq under the symbol INAB.
Financial Metrics
The provided filing text does not include the financial results contained in Exhibit 99.1. Accordingly, it does not provide clear values for revenue, net income or loss, cash flow, operating expenses, margins, cash and cash equivalents, debt, liquidity, or other financial metrics.
Changes Versus Prior Comparable Period
The filing text does not provide a comparison with the quarter ended March 31, 2022 or any other prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The provided text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. It only states that the company issued a press release announcing quarterly financial results.
Important Facts to Verify
- Review Exhibit 99.1 for the actual quarterly financial results and year-over-year comparisons.
- Verify cash balances, quarterly cash burn, and estimated liquidity runway.
- Review any management outlook, financing plans, clinical-development updates, or other risk disclosures in the press release.
- Note that the Form 8-K information, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Exchange Act, except where expressly incorporated by reference.